aromatic L-amino acid decarboxylase deficiency
Also known as AADC deficiency, aromatic L-amino-acid decarboxylase deficiency, Aadc deficiency, DDC deficiency+2 more
AADC deficiency, aromatic L-amino-acid decarboxylase deficiency, Aadc deficiency, DDC deficiency, Dopa decarboxylase deficiency, aromatic amino acid decarboxylase deficiency.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Upstaza is indicated for the treatment of patients aged 18 months and older with a clinic… (2022)
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
AADC deficiency, aromatic L-amino-acid decarboxylase deficiency, Aadc deficiency, DDC deficiency, Dopa decarboxylase deficiency, aromatic amino acid decarboxylase deficiency
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Related entities are derived from literature co-mention (studied together) — associative, not causal.